.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Queensland Health
Farmers Insurance
Baxter
Citi
Merck
Express Scripts
Argus Health
Chinese Patent Office

Generated: September 19, 2017

DrugPatentWatch Database Preview

Ani Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for ANI PHARMS INC, and when can generic versions of ANI PHARMS INC drugs launch?

ANI PHARMS INC has one hundred and twenty-two approved drugs.

There is one US patent protecting ANI PHARMS INC drugs.

There are fourteen patent family members on ANI PHARMS INC drugs in eleven countries.

Summary for Applicant: Ani Pharms Inc

Patents:1
Tradenames:63
Ingredients:59
NDAs:122
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ani Pharms Inc
GLIPIZIDE
glipizide
TABLET;ORAL074387-002Mar 4, 1996DISCNNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
CHLORPROPAMIDE
chlorpropamide
TABLET;ORAL088918-001Oct 16, 1984DISCNNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
PROCAINAMIDE HYDROCHLORIDE
procainamide hydrochloride
TABLET, EXTENDED RELEASE;ORAL088958-001Dec 2, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
IBUPROFEN
ibuprofen
TABLET;ORAL072903-001Dec 19, 1991DISCNNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
THIORIDAZINE HYDROCHLORIDE
thioridazine hydrochloride
TABLET;ORAL088273-001Oct 3, 1983DISCNNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
CHLORPROPAMIDE
chlorpropamide
TABLET;ORAL088921-001Apr 12, 1985ABRXNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
VANCOCIN HYDROCHLORIDE
vancomycin hydrochloride
CAPSULE;ORAL050606-002Apr 15, 1986ABRXYesYes► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
THIORIDAZINE HYDROCHLORIDE
thioridazine hydrochloride
TABLET;ORAL088271-001Apr 14, 1983DISCNNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
CHOLESTYRAMINE
cholestyramine
POWDER;ORAL074554-001Oct 2, 1996DISCNNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
METHAZOLAMIDE
methazolamide
TABLET;ORAL040001-001Jun 30, 1993ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Ani Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ani Pharms Inc
LITHOBID
lithium carbonate
TABLET, EXTENDED RELEASE;ORAL018027-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Ani Pharms Inc
BRETHINE
terbutaline sulfate
TABLET;ORAL017849-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Ani Pharms Inc
BRETHINE
terbutaline sulfate
TABLET;ORAL017849-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Ani Pharms Inc
BRETHINE
terbutaline sulfate
TABLET;ORAL017849-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Ani Pharms Inc
INDERAL LA
propranolol hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL018553-003Apr 19, 1983► Subscribe► Subscribe
Ani Pharms Inc
INDERAL LA
propranolol hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL018553-001Apr 19, 1983► Subscribe► Subscribe
Ani Pharms Inc
BRETHINE
terbutaline sulfate
TABLET;ORAL017849-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Ani Pharms Inc
INDERAL LA
propranolol hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL018553-002Apr 19, 1983► Subscribe► Subscribe
Ani Pharms Inc
INDERAL LA
propranolol hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL018553-004Mar 18, 1987► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Ani Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,040,086Timed, sustained release systems for propranolol► Subscribe
9,358,214Timed, sustained release systems for propranolol► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ani Pharms Inc Drugs

Country Document Number Estimated Expiration
South Korea101090719► Subscribe
Australia2002330211► Subscribe
World Intellectual Property Organization (WIPO)03028708► Subscribe
Norway20041740► Subscribe
South Korea20040084890► Subscribe
European Patent Office1432411► Subscribe
Japan4369752► Subscribe
Austria442134► Subscribe
Japan2005508922► Subscribe
Norway335070► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Ani Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2011 00026Denmark► SubscribePRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
14/008Ireland► SubscribePRODUCT NAME: DEXLANSOPRAZOLE OR A SALT THEREOF; NAT REGISTRATION NO/DATE: PA1864/001/001-002;PA1864/002/001-002 20131125; FIRST REGISTRATION NO/DATE: 47911 47912 47913 47914 20130919
C0005Belgium► SubscribePRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204
C0025Belgium► SubscribePRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
C/GB99/008United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
C0021Belgium► SubscribePRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
80045Netherlands► SubscribePRODUCT NAME: FOSPHENYTOINUM-DI-NATRICUM; NATL REGISTRATION NO/DATE: RVG 22758 19980702; FIRST REGISTRATION: GB PL 00019/0157 19980204
00095Netherlands► SubscribePRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
1999Austria► SubscribePRODUCT NAME: FOSPHENYTOIN-NATRIUM; NAT. REGISTRATION NO/DATE: 1-22664 19980728; FIRST REGISTRATION: GB 00019/0157 19980204
C0021Belgium► SubscribePRODUCT NAME: LANSOPRAZOLE; NAT. REG.: 150 S 539 F 4 19921119; FIRST REG.: FR 333 412.1 19901211
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Mallinckrodt
Fish and Richardson
McKesson
Cerilliant
Cantor Fitzgerald
Daiichi Sankyo
Covington
Argus Health
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot